China, Sept. 29 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'HER2 PET-CT Predicts the Efficacy and Prognosis of Disitamab Vedotin in Treating HER2-Positive Metastatic Urothelial Carcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133489
Registration Time: 2026/09/28
Type: Interventional study
Primary Sponsor: Huashan Hospital, Fudan University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338888
Published by HT Digital Content Services with permission from Health Daily Digest....